PennAlt is a pharmaceutical company dedicated to developing targeted therapies for neurological disorders, utilizing advanced drug formulation techniques to enhance bioavailability and efficacy. The company addresses the significant unmet medical needs of patients suffering from conditions such as epilepsy and multiple sclerosis by providing high-quality, effective treatment options.
Funding
$9.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurological disorders like epilepsy and multiple sclerosis present significant challenges due to limited treatment options and the need for improved drug bioavailability and efficacy. Many patients experience inadequate symptom control and adverse side effects with existing medications.
Solution
Penn Health Group develops targeted therapies for neurological disorders, focusing on advanced drug formulation techniques to enhance bioavailability and efficacy. Their approach aims to address the unmet medical needs of patients suffering from conditions such as epilepsy and multiple sclerosis by providing high-quality, effective treatment options. The company is committed to improving patient outcomes through innovative pharmaceutical solutions.
Target Audience
The primary target audience includes patients suffering from neurological disorders such as epilepsy and multiple sclerosis, as well as healthcare providers seeking improved treatment options.
Features
- Targeted therapies for neurological disorders
- Advanced drug formulation techniques
- Enhanced bioavailability
- High-quality treatment options